
Miroculus (acquired by INTEGRA Biosciences)


About
Miroculus (acquired by INTEGRA Biosciences)
Healthcare & Life Sciences
Pharmaceuticals, Diagnostics & Life Sciences
Wearables, Devices and Hardware
USA
Founder :

Fay Christodoulou
Total Capital Raised
$45,000,000
Team Size
Exited (IPO, Acquired)
Year Founded
2014
Year Selected
2020
Year Team Size
21-50
Transforming Disease Detection
Miroculus was a San Francisco-based biotechnology company that disrupted the medical industry and life science with its innovative approach to disease detection. Through its portable lab, Miroculus enabled thousands of scientists, engineers, hospitals and lab operators all over the world to create, share, download and run the most complex protocols and tests in a fully automated fashion. Miroculus created a special technology that automates and simplifies complex genetic processes, like preparing DNA for analysis, in a small, easy-to-use machine. This makes tasks like studying genes or editing cells faster and more efficient. Miroculus IP extended to over 25 patent applications within 13 different patent families. The company raised over $45 million during its operations and successfully exited to Integra, where Fay Christodoulou is now Chief Scientific Officer.
Miroculus in Three:
What problem did Miroculus solve? Miroculus addressed the need for efficient and automated disease detection in the medical and life sciences.
What was innovative about Miroculus? Miraculous' Miro technology utilized digital microfluidics to automate and miniaturize complex genomic protocols, allowing DNA preparation analysis to be analyzed easier.
Who used Miroculus? Thousands of scientists, engineers, hospitals, and lab operators worldwide, including those in the USA, Canada, UK, France, Germany, Austria, Sweden, Switzerland, Japan, and China, used Miroculus's portable lab.
Identifications & Programs